Sulfamethoxazole-Trimethoprim Prophylaxis in Pediatric Oncology Patients With Glucose-6-Phosphate Dehydrogenase Deficiency

Rachael M Stone,Cyrine E Haidar,Nancy M Kornegay,Patricia J Barker,Seth E Karol,Joshua Wolf,Jane S Hankins,Mary V Relling,Kristine R Crews
DOI: https://doi.org/10.1097/INF.0000000000004515
2024-08-07
Abstract:We sought to determine whether Pneumocystis jirovecii pneumonia prophylaxis with sulfamethoxazole-trimethoprim (SMX-TMP) is associated with an increased frequency of acute hemolytic anemia in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency versus non-G6PD-deficient controls in a pediatric oncology population. There was no statistically significant difference in change in hemoglobin or transfusion requirements after starting SMX-TMP between groups. These findings suggest no increased risk of acute hemolytic anemia with SMX-TMP administered at prophylaxis doses in patients with G6PD deficiency.
What problem does this paper attempt to address?